VOY 101
Alternative Names: VOY-101Latest Information Update: 20 Oct 2023
Price :
$50 *
At a glance
- Originator Perceive Biotherapeutics
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Dry age-related macular degeneration
Most Recent Events
- 21 Jun 2023 Phase-I/II clinical trials in Dry age-related macular degeneration (In adults, In the elderly) in Israel (Intravitreous) (NCT06087458)
- 17 Nov 2022 Phase-I/II clinical trials in Dry age-related macular degeneration (In adults, In the elderly) in USA (Intravitreous) (NCT05380492)
- 19 May 2022 Perceive Biotherapeutics plans a phase I/IIa trial in Dry age-related macular degeneration in July 2022 (Intravitreous, Injection) (NCT05380492)